Covalon Announces Promotion of Kim Crooks to Chief Operating Officer and Appointment to Board of Directors
Article content
MISSISSAUGA, Ontario — Covalon Technologies Ltd. (the 'Company' or 'Covalon') (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is pleased to announce the promotion of Ms. Kim Crooks to the position of Chief Operating Officer (COO), effective immediately. In addition to her new role, Ms. Crooks has been appointed to Covalon's Board of Directors.
Article content
Article content
Ms. Crooks rejoined Covalon in early 2024 as Senior Vice President – Operations, bringing with her a wealth of experience from her previous tenure as Vice President of Operations at Covalon from 2012 to 2022. In her role as SVP, she has been instrumental in overseeing production, operations, Quality Assurance, Quality Control, Regulatory Affairs, and Human Resources.
Article content
Brent Ashton, Chief Executive Officer of Covalon Technologies Ltd., stated, 'Kim has done an outstanding job leading our operations since rejoining Covalon at the beginning of 2024. Her leadership has been pivotal in enhancing our operational efficiency and aligning our processes with our strategic objectives. I could not be more excited for Kim to take on this expanded role as COO and to join our Board of Directors. Her deep understanding of our operations and commitment to the growth of our company make her an invaluable asset to our leadership team and Board of Directors.'
Article content
Ms. Crooks will be granted 150,000 stock options that will vest equally over three years at an exercise price equal to the market price of the Company's common shares at the date of grant.
Article content
Ms. Crook's appointment to Covalon's Board of Directors and stock option grant are subject to the approval of the TSX Venture Exchange.
Article content
About Covalon
Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at www.covalon.com.
Article content
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Article content
This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as 'seek', 'anticipate', 'plan', 'estimate', 'expect', 'intend', or variations of such words and phrases or state that certain actions, events, or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur', or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the 'Risks and Uncertainties' section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
15 minutes ago
- CBC
'It's happening. It's real': Northlander passenger train on track to return next year
Some 14 years after it was scrapped by the previous Liberal government and eight years after the current Progressive Conservative promised to bring it back, the Northlander passenger train is set to return in 2026. "Literally we are on track as we speak," said Al Spacek, chair of the Ontario Northland Transportation Commission said. "The equipment is being manufactured and we've seen some exciting developments. Our staff have been down to the manufacturing facility. So it's happening. It's real." Spacek said the passenger service will be fully accessible, complete with Wi-Fi for guests. He also added that improvements are being made to the rail track. "This government has already invested over $70 million on upgrading the track between North Bay and Timmins," he said. "It will be a nice, smooth ride and this only represents 42 per cent of the work that's being planned on the track." Spacek said it's not yet known exactly how much it will cost to bring the Northlander back, but said the provincial government has spent "hundreds of millions of dollars" so far. "We've come a long way since the previous government said they're going to shut down this service," he said. "I'm not sure there was a lack of demand or ridership... certainly that was a decision by the previous government to shut it down for whatever reasons." Liberal Premier Kathleen Wynne did indeed cite low ridership and high costs in 2012, when her government decided to scrap the Northlander passenger train and redirect that funding into Ontario Northland's passenger bus service. In 2011, the Northlander had 39,000 riders, with an annual subsidy of $100 million keeping the train running. By comparison, the 2022 business case for bringing back the train estimated annual operating costs at around $283 million, with as much as $93 million in revenues, if they hit a target of 58,000 riders by 2041. "Ticket prices haven't been determined yet, but this is a public transportation service so the cost will be subsidized. Affordability is a priority," said Spacek. "It's a right that people have access to public transportation. Passenger service doesn't make money. That's the fact of life."
CBC
15 minutes ago
- CBC
Sask. to put American-made booze back on the shelves
The Saskatchewan Liquor and Gaming Authority (SLGA) is resuming the purchase and distribution of American-made alcohol. All American alcohol products will now be available for purchase through all distribution centres and private liquor distributors in the province, said David Morris, a spokesperson for the corporation, in a statement to CBC on Tuesday. "This change gives Saskatchewan people the option to choose whether they want to buy these products or consider alternatives," Morris said. The federal government's 25-per-cent tariff on U.S. alcohol remains in effect. Morris said Saskatchewan consumers are still encouraged to support Saskatchewan and Canadian products when there is an option. The change comes nearly three months after the province reversed its decision to stop selling some American-branded alcohol products made in Canada. In March, the province announced a ban on all American alcohol products. It then walked back that ban for 54 brands that, while American-owned, are produced in Canada.
CTV News
38 minutes ago
- CTV News
Ontario's Life Services Innovation Fund gets $6.5M
Ontario's Life Services Innovation Fund gets $6.5M More than a dozen companies are being awarded up to $500K each to develop new medical treatment technology.
